Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E35.11 EPS (ttm)2.21 Insider Own0.06% Shs Outstand2.66B Perf Week-2.42%
Market Cap205.65B Forward P/E16.43 EPS next Y4.71 Insider Trans-50.43% Shs Float2.60B Perf Month3.12%
Income5.95B PEG3.68 EPS next Q1.05 Inst Own78.00% Short Float2.66% Perf Quarter11.30%
Sales41.73B P/S4.93 EPS this Y29.20% Inst Trans0.65% Short Ratio5.94 Perf Half Y24.21%
Book/sh12.18 P/B6.36 EPS next Y8.59% ROA3.90% Target Price79.12 Perf Year41.35%
Cash/sh3.87 P/C20.00 EPS next 5Y9.54% ROE10.10% 52W Range52.83 - 80.19 Perf YTD37.59%
Dividend2.20 P/FCF54.61 EPS past 5Y-1.90% ROI8.70% 52W High-3.45% Beta0.74
Dividend %2.84% Quick Ratio1.20 Sales past 5Y-3.20% Gross Margin67.40% 52W Low46.55% ATR1.65
Employees69000 Current Ratio1.40 Sales Q/Q4.50% Oper. Margin17.80% RSI (14)58.62 Volatility2.62% 1.96%
OptionableYes Debt/Eq0.73 EPS Q/Q- Profit Margin8.00% Rel Volume1.34 Prev Close76.72
ShortableYes LT Debt/Eq0.61 EarningsJan 24 BMO Payout152.00% Avg Volume11.62M Price77.42
Recom1.80 SMA201.60% SMA505.41% SMA20020.15% Volume15,423,666 Change0.91%
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Dec-10-18 05:45PM  Merck (MRK) Outpaces Stock Market Gains: What You Should Know Zacks
04:30PM  Mercks President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer Business Wire
12:17PM  Roche's Tecentriq Gets FDA Approval for First-Line NSCLC Zacks
10:11AM  PFE Stock Has Broken Its Slump and Could Challenge Former Highs InvestorPlace
Dec-09-18 09:53PM  Here is What Hedge Funds Are Thinking About Merck & Co., Inc. (MRK) Insider Monkey
Dec-07-18 04:11PM  New Biotech IPO Dropped a Unicorn-Sized Value on Its First Day Bloomberg
03:14PM  Mallinckrodt (MNK) to Separate Generics & Branded Businesses Zacks
Dec-06-18 11:20AM  These 16 Top-Rated Stocks Are Showing Strength In Volatile Market Investor's Business Daily
10:40AM  AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study Zacks
09:18AM  Your first trade for Thursday, December 6 CNBC
08:30AM  BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference GlobeNewswire
Dec-05-18 09:14AM  Mylan Expands Recall of Valsartan to All Unexpired Lots Zacks
09:00AM  Are Options Traders Betting on a Big Move in Merck (MRK) Stock? Zacks
07:00AM  Today's Research Reports on Trending Tickers: Pfizer and Merck & Co. ACCESSWIRE
Dec-04-18 06:29PM  Merck KGaA Partners With Startup for Image Tagging Software Bloomberg
05:25PM  Incyte (INCY) Announces Positive Data on Jakafi for GVHD Zacks
06:00AM  3 Big Pharma Stocks Hitting 52-Week Highs -- Are They Buys? Motley Fool
Dec-03-18 05:45PM  Merck (MRK) Stock Sinks As Market Gains: What You Should Know Zacks
09:47AM  Shire's Takhzyro Gets European Nod for Hereditary Angioedema Zacks
09:16AM  Does Keytruda's Dominance Make Merck & Co. a Buy Now? Motley Fool
08:32AM  The Zacks Analyst Blog Highlights: General Motors, Boeing, Microsoft, Merck and UnitedHealth Zacks
06:45AM  Merck to Present at the Citi 2018 Global Healthcare Conference Business Wire
Nov-30-18 03:19PM  Novartis' Gilenya Approved in EU for Expanded Population Zacks
09:56AM  Key Pharma Players With HIV Focus Ahead of World Aids Day Zacks
09:24AM  Fridays Vital Data: McDonalds, Twitter and Merck InvestorPlace
09:11AM  The Zacks Analyst Blog Highlights: Boeing, Merck, Microsoft, UnitedHealth and American Express Zacks
09:06AM  Bayer (BAYRY) to Restructure Business & Reduce Headcount Zacks
09:01AM  The Zacks Analyst Blog Highlights: Merck, Mastercard, Salesforce, Diageo and State Street Zacks
07:23AM  Dow 30 Stock Roundup: BA's $383M Modification Contract, MSFT's Army Contract Zacks
Nov-29-18 07:23PM  [$$] Another Bad Deal for Bayer The Wall Street Journal
04:21PM  Merck (MRK) Receives Approval for 2 HIV Medicines in EU Zacks
04:05PM  Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech Investor's Business Daily
12:05PM  Bayer to sell businesses, cut jobs after Monsanto deal Reuters
10:38AM  Bayer to sell businesses, cut jobs after Monsanto deal Reuters
09:08AM  Dow Records Highest Single Day Gain in 8 Months: 5 Picks Zacks
08:33AM  Catalyst's Firdapse Receives FDA Approval for Rare Disease Zacks
08:10AM  4 Big Pharma Stocks to Add to Your Portfolio in December Zacks
08:09AM  The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Benzinga
Nov-28-18 06:36PM  Merck raised prices five drugs including Keytruda in November Reuters
05:09PM  Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity Zacks
04:30PM  European Commission Approves Mercks DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients Business Wire
Nov-27-18 07:51PM  [$$] Drugmakers Gain More Access to China, but at a Price The Wall Street Journal
06:17PM  Accenture Brings Open Partner Ecosystem for Drug Discovery Zacks
05:50PM  Merck (MRK) Outpaces Stock Market Gains: What You Should Know Zacks
04:40PM  This Pharma Giant Is Still Consolidating Despite Lung Cancer Flop Investor's Business Daily
03:41PM  Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate Zacks
03:33PM  Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial Zacks
10:39AM  Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease Zacks
Nov-26-18 05:37PM  AMAG's Label Expansion of Lead Products Raises Share Price Zacks
11:33AM  Bayer looks at options for consumer brands, animal health - sources Reuters
10:22AM  Bayer discusses sale of some consumer brands, future of animal health-sources Reuters
09:33AM  Glaxo Inks Marketing Deal for Anaemia Candidate in Japan Zacks
Nov-23-18 02:05PM  Bayer Hurts from Generic Competition & Pipeline Setbacks Zacks
Nov-22-18 09:16AM  Pfizer's FDA Nod for Cancer Drug is Four in a Row in 90 Days Zacks
09:10AM  New Trends in Healthcare Push Stocks Higher: 5 Picks Zacks
Nov-21-18 05:50PM  Merck (MRK) Gains But Lags Market: What You Should Know Zacks
02:17PM  Pfizer Stock Has Multiple Positive Catalysts InvestorPlace
01:42PM  Not business as usual: Rockville biotechs new CEO wants to turn things around American City Business Journals
10:48AM  October's Biggest Losers And Most Surprising Winners Benzinga
10:04AM  Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility Zacks
09:58AM  IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance Zacks
09:44AM  FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz Zacks
09:36AM  Shire-Takeda Deal Gets Phase I Conditional European Approval Zacks
08:58AM  TESARO Shares Rally on Rumors of Potential Acquisition Offer Zacks
08:55AM  Amid sell-off, top analysts are getting bullish these 5 defensive stocks including Merck CNBC
08:16AM  Can Deal Interest Help Tesaro Recover? Motley Fool
07:05AM  Today's Research Reports on Trending Tickers: Johnson & Johnson and Merck & Co. ACCESSWIRE
Nov-20-18 06:54PM  UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium GlobeNewswire
08:12AM  Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails Zacks
Nov-19-18 03:23PM  3 Steady Healthcare Stocks to Hold During a Downturn InvestorPlace
09:49AM  AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks
09:35AM  Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs Zacks
07:12AM  Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer PR Newswire
06:30AM  BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium GlobeNewswire
Nov-17-18 05:02PM  Better Buy: Celgene Corporation vs. Merck & Co. Motley Fool
Nov-16-18 08:35AM  Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings Zacks
06:16AM  A Look At Merck & Co Incs (NYSE:MRK) Exceptional Fundamentals Simply Wall St.
Nov-15-18 04:09PM  Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug Zacks
10:01AM  Merck's Keytruda Improves Survival in Esophageal Cancer Study Zacks
09:50AM  MARKETS: Stocks could bounce here, but I'm selling the rally Yahoo Finance Video
Nov-14-18 05:50PM  Merck (MRK) Stock Moves -0.7%: What You Should Know Zacks
03:34PM  AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study Zacks
10:15AM  Merck Starts Rolling BLA Submission for Ebola Vaccine V920 Zacks
09:07AM  Can These 2 Battered Biotech Stocks Recover? Motley Fool
08:17AM  The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut Benzinga
07:15AM  Merck drug Keytruda succeeds in late-stage esophageal cancer trial Reuters
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS 10) Business Wire
06:19AM  Dont Be Fooled by the Recent Selling; Hedge Funds Still Love Merck & Co., Inc. (MRK) Insider Monkey
Nov-13-18 05:20PM  Daniel Loeb Purchases 7 Stocks in 3rd Quarter GuruFocus.com
04:35PM  Merck Begins Rolling Submission of Licensure Application for V920 (rVSVG-ZEBOV-GP) to U.S. Food and Drug Administration Business Wire
01:17PM  Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates Zacks
Nov-12-18 03:46PM  5 Stocks to Sell After the Midterm Election InvestorPlace
01:19PM  October's biggest Losers And Most Surprising Winners Benzinga
09:44AM  Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer Zacks
06:55AM  FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review Business Wire
Nov-09-18 04:21PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib Business Wire
03:17PM  Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update Zacks
02:23PM  Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag Zacks
06:45AM  New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancers 33rd Annual Meeting Business Wire
Nov-08-18 05:50PM  Merck (MRK) Gains As Market Dips: What You Should Know Zacks
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., Daiichi Sankyo Company, Limited, and Cold Genesys, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM